Open AccessStatin induced regression of cardiomyopathy trial: A randomized, placebo-controlled double-blind trial
Author(s) -
Ahmad Hersi,
JPeter Giannoccaro,
Andrew G. Howarth,
Derek V. Exner,
Sarah Weeks,
Ingo Eitel,
RCameron Herman,
Henry J. Duff,
Debbie Ritchie,
Maureen McRae,
Robert S. Sheldon
Publication year - 2016
Publication title -
heart views
Language(s) - English
Resource type - Journals
eISSN - 0976-5123
pISSN - 1995-705X
DOI - 10.4103/1995-705x.201784
Subject(s) - medicine , atorvastatin , placebo , cardiology , hypertrophic cardiomyopathy , clinical endpoint , statin , diastole , cardiomyopathy , randomized controlled trial , heart failure , blood pressure , pathology , alternative medicine
Hypertrophic cardiomyopathy (HCM), characterized by a thickened, fibrotic myocardium, remains the most common cause of sudden cardiac death in young adults. Based on animal and clinical data, we hypothesized that atorvastatin would induce left ventricular (LV) mass regression.